Evidence Intelligence™
- EvidenceScore™
- 74
- Moderate
- ImpactScore™
- 65
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
GLP-1 agonists reduce heart fat thickness in diabetes.
Last updated July 5, 2026
Key finding
Epicardial adipose tissue thickness significantly decreased in the semaglutide group (P < 0.01).
Semaglutide and dulaglutide administered weekly to adults with type 2 diabetes and obesity.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Semaglutide and dulaglutide administered weekly to adults with type 2 diabetes and obesity.
Clinical relevance
This study evaluated Semaglutide and dulaglutide administered weekly to adults with type 2 diabetes and obesity.
Keep in mind
Limitations were not clearly described in the extracted text.
Published in
Journal Reference
Publication details and source links for this paper.
Gianluca I, Alexandra CVF. Weekly administration of GLP-1 receptor agonists semaglutide or dulaglutide reduces epicardial adipose tissue thickness. Journal of the Endocrine Society. 2020;4(4):bvz042. doi:10.1210/jendso/bvz042
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dulaglutide, Metformin, Semaglutide and BMI, Epicardial adipose tissue thickness, HbA1c.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
- BMI
- Epicardial adipose tissue thickness
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
8
Evidence pairs
1120
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and HbA1c
Related evidence
Evidence relationship
Metformin Therapies and HbA1c
Save evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Mass Index
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Epicardial adipose tissue thickness
Dulaglutide → Epicardial adipose tissue thickness
Dulaglutide → Epicardial adipose tissue thickness
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 4 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 73
- generally_consistent
Supporting studies: Based on 12 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 70
- Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
Add to Evidence TrackerEpicardial adipose tissue thickness
Semaglutide → Epicardial adipose tissue thickness
Semaglutide → Epicardial adipose tissue thickness
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 87
- Very Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 16 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, Metformin Therapies and HbA1c.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 87
- Very Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 16 studies
View evidenceMedications
Metformin Therapies → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 73
- generally_consistent
Supporting studies: Based on 12 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
16 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
16 studies
outcome_hubMeasures HbA1c as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
12 studies
intervention_hubContributes to Metformin Therapies evidence base.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
16 results
All studies on Metformin and HbA1c
Intervention: MetforminOutcome: HbA1c
12 results
All studies on Semaglutide
Intervention: Semaglutide
16 results
All studies on Metformin
Intervention: Metformin
12 results
All studies measuring HbA1c
Outcome: HbA1c
16 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists lower HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 88.2 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.
Do Metformin Therapies lower HbA1c?
Strong Evidence
Metformin Therapies appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.3 | strong positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 14 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may affect body mass index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Strong | EvidenceScore™ 85.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 20 supporting studies with consistent results and a positive effect signal.
Do Metformin Therapies affect body mass index?
Strong Evidence
Metformin Therapies may affect body mass index.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 6 supporting studies with generally consistent results and a positive effect signal.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesityVildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesHigher semaglutide doses improve glucose control in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.